Aprecia Pharmaceuticals

Executive Summary

Aprecia Pharmaceuticals is a private drug delivery company pioneering the use of 3D printing technology to develop novel oral solid dosage forms. Founded in 2003 and headquartered in Blue Ash, Ohio, the company’s proprietary ZipDose platform enables the production of rapidly disintegrating, high-dose medications that improve patient compliance and ease of administration, particularly for patients with swallowing difficulties. Aprecia’s first FDA-approved product, Spritam (levetiracetam), for epilepsy, demonstrated the viability of its 3D printing approach. The company continues to expand its pipeline by partnering with pharmaceutical firms to apply its technology to a range of therapeutic areas, including central nervous system disorders and cardiovascular diseases. As a private entity, Aprecia does not disclose financials, but its innovative platform positions it as a key player in the growing field of personalized medicine and advanced manufacturing. The company’s focus on patient-centric solutions and its established regulatory pathway provide a foundation for future growth and potential strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026New partnership or licensing deal with a major pharmaceutical company for ZipDose platform70% success
• Q4 2026FDA approval of a second product using its 3D printing technology50% success
• Q1 2027Series C or later-stage funding round to expand manufacturing capacity60% success